CD8A and neoplasm: As CMS5a tumors reportedly harbor an internal tumor antigen (CMS5a-intAg) recognized by CD8+ T cells,31 we analyzed CD8+ T cell responses against NY-ESO-1 and CMS5a-intAg 5 days after the secondary tumor inoculation.